Skip to main content
. 2017 Jan 30;114(7):1631–1636. doi: 10.1073/pnas.1619667114

Fig. 2.

Fig. 2.

Recombinant IL-37 suppresses the osteogenic responses in AVICs of diseased human aortic valves. AVICs of normal and diseased aortic valves were treated with recombinant IL-37 (0.1 and 1.0 ng/mL) 1 h before stimulation with LPS (0.2 µg/mL) or Pam3CSK4 (PAM, 0.1 µg/mL) for 3–21 d. (A) Representative immunoblots and densitometric data (n = 6 isolates from different donors) show that treatment with recombinant IL-37 results in greater reduction in BMP-2 and ALP levels at 3 d in AVICs of diseased aortic valves. (B) Representative images (n = 5 separate experiments using different isolates) show that recombinant IL-37 reduces calcium deposit formation in diseased cells after 21 d of stimulation in a conditioning medium. (Original magnification: 10×.) *P < 0.05 vs. corresponding control; †P < 0.05 vs. normal cells receiving the same treatment; ‡P < 0.05 vs. stimulant alone.